Weiyang Medical Completes RMB 100 Million Strategic Financing with Landu Healthcare to Build China's Pathogen Surveillance 'Sky Net' Laboratory

Recently,WILLINGMED (Beijing) Micro-Rock Medical Technology Co., Ltd. (hereinafter referred to as “WILLINGMED”) announced the completion of a strategic financing round amounting to hundreds of millions of RMB,This round of financing was led by Shanghai Runda Medical Technology Co., Ltd. (hereinafter referred to as"Runda Medical", A-share code 603108) andGongshu State InvestmentCo-investment, primarilyFor the construction of China’s “Pathogen Microbiology Skynet Laboratory,” enabling rapid detection of complex infections using metagenomic next-generation sequencing (mNGS) technology.

WILLINGMED is an innovative enterprise focused on the field of precision molecular diagnostics for infections, with multiple regional testing centers in Beijing, Hangzhou, Guangzhou, and other areas, integrating technological R&D, medical laboratory services, and the production of reagents and equipment. The company’s team members have, within China, targeted respiratory specimensFirst to LaunchDNA+RNA Pathogen Single-Process Co-Detection Product Significantly Reduces Testing Costs; WILLINGMED Addresses Challenging Blood Samples in ChinaPioneering the Launch of the FirstHypersensitive Dual-Dimensional Bloodstream Infection Detection Product, Significantly Enhancing Detection Sensitivity; Related Products Can Simultaneously Cover Bacteria, Fungi, Viruses, and More24000+Detection of pathogenic microorganisms, with reports issued within 20 hours, has received unanimous acclaim from clinical experts.

Meanwhile, WILLINGMED is actively advancingMore than tenan mNGS IVD pipeline covering applications such as reagents, instruments, and software, with multiple products having completed registration; inmNGS and Microfluidic Automated Chipspossesses multiple core technologies in areas such as,Tensinvention patents and more than ten software copyrights, and has repeatedly achieved perfect scores in the external quality assessment organized by the National Center for Clinical Laboratories of the National Health Commission.

As one of the few companies in the industry capable of delivering high-throughput, fully automated end-to-end solutions, WILLINGMED has innovatively applied mNGS technology to pathogen diagnosis and provided services across China.Over 1,000 hospitals, providing precise testing services for clinical patients in departments such as Infectious Diseases, Respiratory Medicine, Pediatrics, ICU, Neurology, Hematology, and Oncology.

The “China Pathogen Microorganism SkyNet Laboratory” project, jointly established by WILLINGMED and Runda Medical, will focus on precise detection of clinical infectious pathogens, leveraging the superior resources of both parties in laboratory medicine. The first batch is planned toThree Yearswithin ChinaOver 300Joint Establishment of a Pathogen Metagenomic Testing Laboratory in Collaboration with Tier-3 Grade-A Hospitals,Completion of the construction of an intelligent analysis platform for metagenomic data, clinical data, and antimicrobial resistance gene data of pathogenic microorganisms in the Chinese population,Advancing Precision Diagnosis, Treatment, and Prevention of Infectious Diseases in China.

PathoLab, provided by WILLINGMED, covering the entire mNGS workflow^TMPathogen Laboratory System and PathoReport^TMThe intelligent reporting system offers a one-stop, high-throughput automation solution. The “China Pathogen Microbiology SkyNet Laboratory” will establish a nationwide network of pathogen detection laboratories. By integrating multi-dimensional correlated data from the SkyNet Laboratory—including pathogens, patients, drugs, and genomic information—the system enables rapid response in pathogen detection, precision medication, disease epidemic monitoring and early warning, surveillance of emerging infectious diseases, and research and development of clinical diagnostic products. This provides timely, comprehensive, and professional support for clinical diagnosis and treatment as well as government decision-making in epidemic prevention and control.

Hu Zhening, Deputy General Manager of Runda Medical“It was stated that the infectious disease market is vast, with substantial demand and broad prospects; however, the primary clinical pain point lies in diagnosis. As a high-tech enterprise specializing in precision molecular diagnostics for infectious diseases, WILLINGMED’s core team has been deeply engaged in the field of pathogen molecular diagnostics for over a decade. Leveraging extensive industry experience in clinical infectious disease diagnostics and its industry-leading automated mNGS products and services, the company has established a comprehensive full-industry-chain layout covering upstream, midstream, and downstream segments, including instruments and reagents, testing services, and databases. Following this strategic investment, Runda Medical will leverage its robust laboratory network system to empower the clinical application of WILLINGMED’s mNGS technology and support WILLINGMED’s leapfrog development.”

Dr. Gai Wei, CEO of WILLINGMEDHe stated: “We extend our heartfelt gratitude to Runda Medical and Gongshu State-owned Capital Investment for their unwavering support and high recognition of WILLINGMED’s endeavors in the precise diagnosis of pathogenic infections. As one of the few companies in the industry capable of delivering fully automated end-to-end solutions, WILLINGMED will leverage its strengths to assist hospitals in establishing automated mNGS testing platforms. We believe that through this strategic investment, the strong alliance between both parties will accelerate the joint establishment of pathogen metagenomic testing laboratories in 300 large Grade A tertiary hospitals across China. This will enable more advanced diagnostic technologies to yield tangible clinical benefits, providing effective support for disease diagnosis and treatment, and safeguarding human health.”

Shanghai Runda Medical Technology Co., Ltd. (hereinafter referred to as “Runda Medical,” A-share code: 603108) was founded in 1999 and is headquartered in Shanghai, China. As a comprehensive service provider for medical laboratories based in East China with a nationwide presence, the company’s core business is to deliver integrated services, including in-vitro diagnostic (IVD) products and professional technical support, to various medical laboratories through its proprietary comprehensive service system. Currently, Runda Medical owns more than forty wholly-owned or holding subsidiaries across China and overseas, with its business covering most provinces, municipalities, and regions nationwide. Its product offerings span the major sub-sectors of the in-vitro diagnostics (IVD) industry, establishing the company as one of the leading enterprises in IVD product distribution and integrated services in China. To meet the personalized needs of diverse medical institutions, Runda Medical has innovated and continuously optimized the traditional distribution service model in the IVD industry. It now provides tailored total solution services to thousands of clients, earning high recognition from both customers and the market. Additionally, by complementing its core operations with extended value-chain activities such as IVD product research and development, healthcare information system development, and third-party laboratory testing, Runda Medical has formed a unique and comprehensive IVD business ecosystem.

WILLINGMED (Beijing) Co., Ltd. (hereinafter referred to as “WILLINGMED”), headquartered in Beijing, is a high-tech enterprise dedicated to precision diagnosis and personalized medicine for infectious diseases. With over a decade of expertise in the field of precise pathogen detection, WILLINGMED’s core team has innovatively applied pathogen metagenomic next-generation sequencing (mNGS) technology to pathogen diagnosis. The company has completed the registration filings for multiple test kits, developed numerous proprietary detection and analytical technologies, and can detect and report on more than 24,000 types of pathogenic microorganisms—including bacteria, fungi, and viruses—within 20 hours in a single run. Furthermore, WILLINGMED has developed automated molecular laboratories and an intelligent reporting platform, pioneering the industrialization, productization, and automation of mNGS technology. This advancement enables mNGS to move “out of” the laboratory and “into” the clinical laboratories of major hospitals, vigorously promoting the clinical application of its one-stop automated intelligent mNGS detection system. By establishing collaborations with many renowned experts in clinical medicine, molecular biology, and informatics, WILLINGMED represents the world-leading level of “Intelligent Manufacturing in China” in the mNGS sector, continuously contributing to the health of people across China and around the world.